Chikungunya Virus Vaccine – What we know so far?

Bharat Biotech International’s Chikungunya vaccine candidate is in Phase 2/3 trials in Costa Rica, with patients from Panama and Colombia expected. Valneva’s vaccine candidate has produced neutralizing antibodies in 98.5% of volunteers.

Chikungunya Virus Vaccine

Chikungunya is a mosquito-borne viral disease causing fever, joint pain, muscle pain, joint swelling, headache, nausea, fatigue, and rash, originating from the Makonde people’s language in Mozambique and Tanzania.

This is usually brought on by crippling joint pain that can continue for weeks or even years. Nine clinical trial locations—in Guatemala, Costa Rica, Panama, Columbia, Thailand, and other countries where Chikungunya is endemic—will host the tests.

Costa Rica’s Phase 2/3 clinical trial, funded by CEPI and India Centric Epidemic Preparedness mission, evaluates Bharat Biotech’s BBV87 vaccine candidate’s safety and immune response in healthy adults.

WhatsApp Channel Join Button

Chikungunya Disease

Chikungunya, a mosquito-transmitted disease, has caused at least 5 million infections in the past 15 years, posing a global health threat. Symptoms include fever, viremia, joint pain, and maculopapular rash, affecting all sexes and age groups.

More than half of the patients in earlier investigations had the persistent illness, which led to debilitating polyarthritis.9. The estimated case-fatality ratio is 0·3–1 per 1000, and the majority of deaths are documented in older individuals, neonates, and adults with underlying medical problems.

Vaccination has historically been the most effective strategy for protecting populations and eradicating infectious diseases. Recent vaccine approaches for Chikungunya have shown safe immune responses in animal models and humans.

Chikungunya Virus Vaccine

Vaccination Therapy

The single-dose vaccination “Ixchiq” from Valneva Austria GmbH is approved for use in adults who are more susceptible to contracting the virus. Ixchiq was designated for breakthrough therapy and fast-track treatment.

With at least 5 million instances in the last 15 years though deaths and serious sickness are uncommon, health professionals view it as a growing hazard to world health that is made worse by climate change.

In 99% of individuals tested, twenty-eight days after a single dosage, neutralizing antibodies against the chikungunya virus were found at a level thought to protect against illness.

Chikungunya Virus Symptoms

Chikungunya virus symptoms typically begin 3-7 days after a mosquito bite, including fever, joint pain, headache, muscle pain, swelling, or rash. Chikungunya rarely results in death.

Severe cases include newborns, older adults, and those with medical conditions. Most patients recover within a week, but joint pain can persist.

Diagnosing Chikungunya Virus 

If you exhibit the symptoms listed above and have been in an area where the chikungunya virus has been detected, consult your healthcare professional.

Inform your medical professional of your travel dates and destinations.

To check for chikungunya or other related viruses like dengue and Zika, your healthcare professional may prescribe blood testing.

Vaccine Test 

Valneva’s VLA1553 chikungunya vaccine candidate, a weakened version of the live virus, is being assessed in phase 3 clinical trials, potentially unsuitable for those with weakened immune systems or pregnant women.

In this new study, 4,115 healthy adults from all over the US participated. A single dose of VLA1553 was injected into the arms of 75% of the participants, whereas the remaining individuals received a placebo.

The Lancet’s study found the vaccine was generally well-tolerated across all age groups, with mild or moderate adverse events including headaches, fatigue, muscle or joint pain, and injection site pain.

Serious adverse events occurred in 2% of VLA1553-exposed participants and 1% of placebo-exposed ones, including mild muscle pain and fever, but neither resulted in death.

Immune Response 

Protection from pathogen infections requires innate and adaptive immunity. Alphaviruses induce type-I IFN responses, with elevated IFN-α levels in CHIKV-infected patients. Antigen-presenting cells, including Langerhans, macrophages, and dendritic cells, induce innate immune responses.

Protection from pathogen infections requires innate and adaptive immunity. Alphaviruses induce type-I IFN responses, with elevated IFN-α levels in CHIKV-infected patients. Antigen-presenting cells, including Langerhans, macrophages, and dendritic cells, induce innate immune responses.

Consumers Statistics who pay for Vaccine

We conducted 496 interviews. Twenty-three of these were not included in the analysis. The majority of respondents—57.3% of them were female—had at least a high school diploma (90.7%), were working (87.7%), and had private health insurance (62.6%)

For a single-dose vaccination, the WTP’s median value was US$ 31.17 (120.00 BRL). The WTP exhibited a statistically significant relationship with both the availability of private health insurance and monthly family income.

Chikungunya Virus Vaccination Price 

The price for Chikungunya Vaccination has not been properly disclosed yet. But, soon it will be released.

Visit Rajneetug Homepage To Get Relevant Content.

Leave a Comment